allisartan isoproxil

Allisartan isoproxil is an oral, selective, nonpeptide angiotensin II receptor blocker (ARB) developed in China for the treatment of hypertension. It acts as a prodrug that is hydrolyzed by esterases in the gastrointestinal tract to its active metabolite EXP3174, which selectively blocks the angiotensin II type 1 receptor (AT1R). By inhibiting AT1R, allisartan isoproxil prevents angiotensin II-induced vasoconstriction and aldosterone secretion, resulting in vasodilation and reduced blood pressure. Clinical studies have demonstrated its efficacy in lowering systolic and diastolic blood pressure in patients with mild-to-moderate essential hypertension. The drug also shows organ-protective effects on the heart, kidneys, and vascular endothelium with a favorable safety profile[3][4][5][6][7][8].

Brand names

XinlitanShun Li Tan

Other names

Allisartan isoproxil